Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: a review

被引：20
作者：
Diel, Ingo J.
机构：
[1] CGG Klin GmbH, D-68161 Mannheim, Germany
[2] Inst Gynecol Oncol, Mannheim, Germany
来源：
SUPPORTIVE CARE IN CANCER | 2007年 / 15卷 / 11期
关键词：
bisphosphonates; bone metastases; pain; quality of life; breast cancer;
D O I：
10.1007/s00520-007-0244-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Introduction Almost all patients with breast cancer and bone metastases suffer bone pain. Many receive bisphosphonate therapy only when the pain becomes unbearable or there is a direct threat of skeletal complications. Discussion However, clinical trial data demonstrate that bisphosphonates offer significant and sustained relief from bone pain and can also improve quality of life in patients with metastatic breast cancer. Conclusion Moreover, new treatment schedules using high dose bisphosphonates can offer rapid relief of acute, severe bone pain.
引用
收藏
页码：1243 / 1249
页数：7
相关论文
共 34 条
[1]  
[Anonymous], COCHRANE DATABASE SY
[2]   Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies [J].
Body, JJ ;
Diel, IJ ;
Lichinitzer, M ;
Lazarev, A ;
Pecherstorfer, M ;
Bell, R ;
Tripathy, D ;
Bergstronn, B .
BRITISH JOURNAL OF CANCER, 2004, 90 (06) :1133-1137
[3]   Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases [J].
Body, JJ ;
Diel, IJ ;
Lichinitser, MR ;
Kreuser, ED ;
Dornoff, W ;
Gorbunova, VA ;
Budde, M ;
Bergström, B .
ANNALS OF ONCOLOGY, 2003, 14 (09) :1399-1405
[4]   Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer [J].
Body, JJ ;
Diel, IJ ;
Bell, R ;
Pecherstorfer, M ;
Lichinitser, MR ;
Lazarev, AF ;
Tripathy, D ;
Bergström, B .
PAIN, 2004, 111 (03) :306-312
[5]   Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy [J].
Clemons, Mark J. ;
Dranitsaris, George ;
Ooi, Wei S. ;
Yogendran, Geetha ;
Sukovic, Tatjana ;
Wong, Betty Y. L. ;
Verma, Sunil ;
Pritchard, Kathleen I. ;
Trudeau, Maureen ;
Cole, David E. C. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (30) :4895-4900
[6]  
CONTE PF, 1996, J CLIN ONCOL, V14, P2352
[7]  
Diel I J, 2000, Clin Breast Cancer, V1, P43, DOI 10.3816/CBC.2000.n.003
[8]   Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer [J].
Diel, IJ ;
Body, JJ ;
Lichinitser, MR ;
Kreuser, ED ;
Dornoff, W ;
Gorbunova, VA ;
Budde, M ;
Bergström, B .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (11) :1704-1712
[9]  
DONNELLY S, 1995, SEMIN ONCOL, V22, P67
[10]  
Heidenreich A., 2003, EJC Supplements, V1, pS270, DOI 10.1016/S1359-6349(03)90923-2
1234